In a study by Rath and others, they investigated factors associated with vedolizumab efficacy in patients with IBD and found that vedolizumab treatment reduces the expression of the α4β7 integrin on Th1, Th2, and Th17 polarized cluster of differentiation CD4+ T cells (Rath et al., 2018). Here, CD4 is linked to inflammatory bowel disease.